Automated GMP compliant production of [18F]AlF-NOTA-octreotide
EJNMMI Radiopharmacy and Chemistry, 2020 Background Gallium-68 labeled synthetic somatostatin analogs for PET/CT imaging are the current gold standard for somatostatin receptor imaging in neuroendocrine tumor patients.
Térence Tshibangu +7 more
doaj +2 more sources
Frontiers in Pharmacology, 2021 Background: Terlipressin is the first-line pharmacological treatment for hepatorenal syndrome. When terlipressin is unavailable, midodrine/octreotide or norepinephrine, with albumin, represent the alternative treatments. The comparative efficacy of these
Eman Ibrahim El-Desoki Mahmoud +4 more
doaj +2 more sources
Diagnostic efficiency of 68Ga-DOTATATE PET/CT as compared to 99mTc-Octreotide SPECT/CT and conventional morphologic modalities in neuroendocrine tumors [PDF]
Asia Oceania Journal of Nuclear Medicine and Biology, 2019 Objective(s): In view of somatostatin receptor (SSR) expression on cell membranes of the majority of neuroendocrine tumors (NETs), functional imaging exploiting analogs of SSR alongside the anatomical imaging is the mainstay of this diagnostic modality ...
Babak Fallahi +8 more
doaj +2 more sources
New medical therapies on the horizon: oral octreotide [PDF]
Pituitary, 2017 Somatostatin analog treatment is first line medical treatment in patients with acromegaly. This drug is currently mainly administered by monthly depot preparations of octreotide and lanreotide.
Nienke R. Biermasz
openalex +2 more sources
Expert Opinion on Drug Delivery, 2021 Introduction The FDA approval of oral semaglutide for type 2 diabetes (2019) and oral octreotide for acromegaly (2020) is evidence that selected niche peptides can be administered orally if formulated with selected intestinal permeation enhancers.
David J Brayden, S. Maher
semanticscholar +1 more source
Challenges in Diagnosis and Management of Ovarian Neuroendocrine Carcinoma: A Case of Aggressive Disease With Multimodal Treatment Approach. [PDF]
Clin Case RepABSTRACT Neuroendocrine tumors (NETs) of the ovary are extremely rare, accounting for only 1%–2% of malignant ovarian tumors, with high‐grade subtypes demonstrating particularly aggressive behavior. We describe a 47‐year‐old woman who presented with abdominal swelling, irregular bleeding, and pain, and was diagnosed with high‐grade ovarian ...
Haider J +6 more
europepmc +2 more sources
Clinical Cancer Research, 2020 Purpose: Aggressive meningiomas that progress after surgery/radiotherapy represent an unmet medical need. Strong and constant expression of SSTR2A receptors and activation of the Pi3K/Akt/mTOR pathway have been demonstrated in meningiomas.
T. Graillon +21 more
semanticscholar +1 more source
The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth [PDF]
, 1994 A 52-year-old female with metastatic glucagonoma secreting glucagon and chromogranin A was treated with the somatostatin analogue octreotide for 2 years without any additional tumor-reducing interventions. Before therapy plasma glucagon was above 8 μg/l (
Jockenhövel, F. (F.) +6 more
core +12 more sources
Journal of Medical Case Reports, 2011 Introduction The safety of octreotide use, in its short-acting preparation, in pregnancy is still unclear. This report provides the first documentation of uneventful octreotide LAR use during three pregnancies in a woman with bronchial carcinoid ...
Naccache Deeb +5 more
doaj +1 more source
Growth Hormone (GH)-Releasing Peptide Stimulation of GH Release from Human Somatotroph Adenoma Cells: Interaction with GH-Releasing Hormone, Thyrotropin- Releasing Hormone, and Octreotide. [PDF]
, 1994 The synthetic hexapeptide GH-releasing peptide (GHRP; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) specifically stimulates GH secretion in humans in vivo and in animals in vitro and in vivo via a still unknown receptor and mechanism.
Brockmeier, S. +7 more
core +1 more source